TARRYTOWN, N.Y. and
PARIS, Sept. 19, 2021 /PRNewswire/ --
Phase 3 trial met its primary and key secondary
endpoints
Libtayo is one of two PD-(L)1 inhibitors to demonstrate
positive Phase 3 results in first-line advanced NSCLC irrespective
of histology both as monotherapy and in combination with
chemotherapy
Trial enrolled patients with varied baseline characteristics,
including squamous and non-squamous histologies and all PD-L1
expression levels; 84% had an ECOG 1 performance status (reduced
daily functioning)
Regeneron will host investor webcast on Monday, September 20 to discuss results and
broader oncology portfolio
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi
announced positive Phase 3 results for a Libtayo®
(cemiplimab) combination treatment were presented today during a
late-breaking session at the European Society for Medical Oncology
Virtual Congress 2021. The trial, which met its primary overall
survival (OS) endpoint and all key secondary endpoints, assessed
the investigational use of PD-1 inhibitor Libtayo in combination
with a physician's choice of platinum-doublet chemotherapy (Libtayo
combination) in patients with locally advanced or metastatic
non-small cell lung cancer (NSCLC) irrespective of histology and
across all PD-L1 expression levels, compared to chemotherapy alone.
These results were also achieved in a patient population with
varied baseline characteristics and will form the basis of
regulatory submissions, including in the U.S. and European Union
(EU).
"Libtayo added to chemotherapy significantly improved patient
outcomes, extending median overall survival to 22 months and median
progression-free survival to 8 months," said Miranda
Gogishvili, M.D., an oncologist at the High Technology Medical
Center University Clinic, in Tbilisi,
Georgia and a trial investigator. "Exploratory analyses
showed that survival improvements were seen across squamous and
non-squamous histologies and in patients with reduced daily
functioning, with 43% of patients having squamous disease and 84%
having an ECOG 1 performance status. Furthermore, in another
exploratory analysis, the Libtayo combination helped delay
deterioration in patient-reported quality of life and pain
symptoms."
In the overall population, patients treated with the Libtayo
combination (n=312) experienced significant improvements compared
to those receiving chemotherapy alone (n=154), including a:
- 22-month median OS compared to 13 months for
chemotherapy, representing a 29% relative reduction in the risk
of death (hazard ratio [HR]: 0.71; 95% confidence interval
[CI]: 0.53 to 0.93; p=0.014). The 12-month probability of survival
was 66% for the Libtayo combination and 56% for chemotherapy.
- 8-month median progression-free survival (PFS) compared
to 5 months for chemotherapy, representing a 46% relative
reduction in the risk of disease progression (HR: 0.56;
95% CI: 0.44 to 0.70; p<0.0001). The 12-month probability of PFS
was 38% for the Libtayo combination and 16% for chemotherapy.
- 43% objective response rate (ORR) compared
to 23% for chemotherapy.
- 16-month median duration of response (DOR) compared
to 7 months for chemotherapy.
Favorable patient-reported outcomes were also observed.
Specifically, the Libtayo combination delayed deterioration in pain
symptoms (HR: 0.39; 95% CI: 0.26 to 0.60; nominal p<0.0001) and
showed a trend towards delayed deterioration in global health
status/quality of life (HR: 0.78; 95% CI: 0.51 to 1.19; nominal
p=0.248), compared to chemotherapy. The Libtayo combination also
improved pain symptoms, compared to chemotherapy (-4.98 difference
in baseline changes between treatment groups; 95% CI: -8.36 to
-1.60; nominal p=0.004).
No new Libtayo safety signals were identified. The median
duration of exposure was 38 weeks for the Libtayo combination
(n=312) and 21 weeks for chemotherapy (n=153). Adverse
events (AEs) of any grade occurred in 96% of patients receiving the
Libtayo combination and 94% of patients receiving chemotherapy
alone, with 19% and 0% being immune-mediated, respectively. For the
Libtayo combination and chemotherapy groups, the most common AEs
were anemia (44%, 40%), alopecia (37%, 43%) and nausea (25%,
16%); grade ≥3 AEs occurring in ≥5% of patients were anemia
(10%, 7%) and neutropenia (both 6%). Treatment
discontinuation due to AEs occurred in 5% of patients
receiving the Libtayo combination and 3% receiving
chemotherapy.
"This Phase 3 trial was stopped early because Libtayo
significantly improved overall survival compared to chemotherapy, a
milestone also achieved by our Phase 3 trial for Libtayo
monotherapy as a first-line treatment for advanced non-small cell
lung cancer with high PD-L1 expression," said Israel Lowy, M.D., Ph.D., Senior Vice President,
Translational and Clinical Sciences, Oncology at Regeneron. "Both
trials were designed to reflect everyday clinical practice by
allowing for the enrollment of patients with difficult-to-treat
disease characteristics. And this is the second Libtayo trial to
demonstrate significant improvement in its primary and key
secondary endpoints for these patient populations, compared to
chemotherapy."
Lung cancer is the leading cause of cancer death worldwide. In
2020, an estimated 2.2 million and 225,000 new cases were diagnosed
globally and in the U.S., respectively. Approximately 84% of all
lung cancers are NSCLC, with 75% of these cases diagnosed in
advanced stages. While PD-1 inhibitor monotherapy has primarily
advanced the treatment of NSCLC with ≥50% PD-L1 expression,
approximately 70% of all NSCLC cases will have <50% PD-L1
expression, making it the most common treatment setting.
"These data add to the growing body of evidence supporting the
use of Libtayo in patients with advanced non-small cell lung
cancer," said Peter C. Adamson,
M.D., Global Development Head, Oncology and Pediatric Innovation at
Sanofi. "With additional trials underway investigating Libtayo as
the backbone in combinations with conventional and novel
therapeutic approaches, we are encouraged by the potential to
further improve outcomes for patients with difficult-to-treat
cancers."
The use of Libtayo in combination with chemotherapy for advanced
NSCLC is investigational, and its safety and efficacy have not been
fully evaluated by any regulatory authority.
Investor Webcast Information
Regeneron will host a
conference call and simultaneous webcast to share updates on
Regeneron's oncology portfolio on Monday,
September 20 at 8:30 a.m. ET.
To access this call, dial 888 660 6127 (U.S.) or +1 973 890 8355
(International). A link to the webcast may be accessed from the
"Investors and Media" page of Regeneron's website at
www.regeneron.com. A replay of the conference call and webcast will
be archived on the Company's website and will be available for at
least 30 days.
About the Phase 3 Trial
The randomized, multicenter
Phase 3 trial, called EMPOWER-Lung 3, investigated a first-line
combination treatment of Libtayo and platinum-doublet chemotherapy,
compared to platinum-doublet chemotherapy alone. The trial enrolled
466 patients with locally advanced or metastatic NSCLC, as well as
squamous or non-squamous histologies across all PD-L1 expression
levels and with no ALK, EGFR and ROS1 aberrations.
Patients were randomized 2:1 to receive either Libtayo 350 mg
(n=312) or placebo (n=154) administered intravenously every 3 weeks
for 108 weeks, plus platinum-doublet chemotherapy administered
every 3 weeks for 4 cycles. The primary endpoint was OS, and key
secondary endpoints were PFS and ORR. The probability of survival
and PFS at 12 months were calculated according to Kaplan-Meier
estimates.
Notably, patients in the trial had a variety of baseline
characteristics commonly considered difficult-to-treat. Among those
enrolled, 43% had tumors with squamous histology, 67% had tumors
with <50% PD-L1 expression, 15% had inoperable locally advanced
disease not eligible for definitive chemoradiation, and 7% had
pretreated and clinically stable brain metastases. Additionally,
84% of patients had an ECOG 1 performance status. ECOG performance
status assesses patient ability to conduct daily living activities
and prognosis on a scale of increasing severity ranging from 0 (no
symptoms) to 5 (death).
About Libtayo
Libtayo is a fully human monoclonal
antibody targeting the PD-1 immune checkpoint receptor on T-cells.
By binding to PD-1, Libtayo has been shown to block cancer cells
from using the PD-1 pathway to suppress T-cell activation.
The generic name for Libtayo in its approved U.S. indications is
cemiplimab-rwlc, with rwlc as the suffix designated in accordance
with Nonproprietary Naming of Biological Products Guidance for
Industry issued by the U.S. FDA. Libtayo is being jointly developed
by Regeneron and Sanofi under a global collaboration agreement.
The extensive clinical program for Libtayo is focused on
difficult-to-treat cancers. Libtayo is currently being investigated
in advanced cervical cancer, as well as in trials combining Libtayo
with either conventional or novel therapeutic approaches for other
solid tumors and blood cancers. These potential uses are
investigational, and their safety and efficacy have not been
evaluated by any regulatory authority.
About
Regeneron's VelocImmune® Technology
Regeneron's
VelocImmune technology utilizes a proprietary genetically
engineered mouse platform endowed with a genetically humanized
immune system to produce optimized fully human antibodies. When
Regeneron's President and Chief Scientific Officer George D. Yancopoulos was a graduate student
with his mentor Frederick W. Alt in
1985, they were the first to envision making such a
genetically humanized mouse, and Regeneron has spent decades
inventing and developing VelocImmune and related
VelociSuite® technologies. Dr. Yancopoulos and
his team have used VelocImmune technology to create
approximately a quarter of all original, FDA-approved and
authorized fully human monoclonal antibodies currently available.
This includes REGEN–COV™ (casirivimab with imdevimab),
Dupixent® (dupilumab), Libtayo®
(cemiplimab-rwlc), Praluent® (alirocumab),
Kevzara® (sarilumab), Evkeeza®
(evinacumab-dgnb) and Inmazeb™ (atoltivimab, maftivimab and
odesivimab-ebgn).
IMPORTANT SAFETY INFORMATION AND INDICATION FOR U.S.
PATIENTS
What is Libtayo?
Libtayo is a prescription medicine
used to treat people with a type of skin cancer called cutaneous
squamous cell carcinoma (CSCC) that has spread or cannot be cured
by surgery or radiation.
Libtayo is a prescription medicine used to treat people with a
type of skin cancer called basal cell carcinoma that cannot be
removed by surgery (locally advanced BCC) and have received
treatment with a hedgehog inhibitor (HHI), or cannot receive
treatment with an HHI.
Libtayo is a prescription medicine used to treat people with a
type of skin cancer called basal cell carcinoma that has spread
(metastatic BCC) and have received treatment with an HHI, or cannot
receive treatment with an HHI. This use is approved based on how
many patients responded to treatment and how long they responded.
Studies are ongoing to provide additional information about
clinical benefit.
Libtayo is a prescription medicine used to treat people with a
type of lung cancer called non-small cell lung cancer (NSCLC).
Libtayo may be used as your first treatment when your lung cancer
has not spread outside your chest (locally advanced lung cancer)
and you cannot have surgery or chemotherapy with radiation, or your
lung cancer has spread to other areas of your body (metastatic lung
cancer), and your tumor tests positive for high "PD-L1" and your
tumor does not have an abnormal "EGFR"," ALK "or "ROS1" gene.
It is not known if Libtayo is safe and effective in
children.
What is the most important information I should know about
Libtayo?
Libtayo is a medicine that may treat certain
cancers by working with your immune system. Libtayo can cause your
immune system to attack normal organs and tissues in any area of
your body and can affect the way they work. These problems can
sometimes become severe or life-threatening and can lead to death.
You can have more than one of these problems at the same time.
These problems may happen anytime during treatment or even after
your treatment has ended.
Call or see your healthcare provider right away if you
develop any new or worsening signs or symptoms, including:
- Lung problems: cough, shortness of breath, or chest
pain
- Intestinal problems: diarrhea (loose stools) or more
frequent bowel movements than usual, stools that are black, tarry,
sticky or have blood or mucus, or severe stomach area (abdomen)
pain or tenderness
- Liver problems: yellowing of your skin or the whites of
your eyes, severe nausea or vomiting, pain on the right side of
your stomach area (abdomen), dark urine (tea colored), or bleeding
or bruising more easily than normal
- Hormone gland problems: headache that will not go away
or unusual headaches, eye sensitivity to light, eye problems, rapid
heartbeat, increased sweating, extreme tiredness, weight gain or
weight loss, feeling more hungry or thirsty than usual, urinating
more often than usual, hair loss, feeling cold, constipation, your
voice gets deeper, dizziness or fainting, or changes in mood or
behavior, such as decreased sex drive, irritability, or
forgetfulness
- Kidney problems: decrease in your amount of urine, blood
in your urine, swelling of your ankles, or loss of appetite
- Skin problems: rash, itching, skin blistering or
peeling, painful sores or ulcers in mouth or nose, throat, or
genital area, fever or flu-like symptoms, or swollen lymph
nodes
- Problems can also happen in other organs and tissues. These are
not all of the signs and symptoms of immune system problems that
can happen with Libtayo. Call or see your healthcare provider right
away for any new or worsening signs or symptoms, which may include:
chest pain, irregular heartbeat, shortness of breath or swelling of
ankles, confusion, sleepiness, memory problems, changes in mood or
behavior, stiff neck, balance problems, tingling or numbness of the
arms or legs, double vision, blurry vision, sensitivity to light,
eye pain, changes in eyesight, persistent or severe muscle pain or
weakness, muscle cramps, low red blood cells, or bruising
- Infusion reactions that can sometimes be severe. Signs
and symptoms of infusion reactions may include: nausea, chills or
shaking, itching or rash, flushing, shortness of breath or
wheezing, dizziness, feel like passing out, fever, back or neck
pain, or facial swelling.
- Rejection of a transplanted organ. Your healthcare
provider should tell you what signs and symptoms you should report
and monitor you, depending on the type of organ transplant that you
have had.
- Complications, including graft-versus-host disease (GVHD),
in people who have received a bone marrow (stem cell) transplant
that uses donor stem cells (allogeneic). These complications
can be serious and can lead to death. These complications may
happen if you underwent transplantation either before or after
being treated with Libtayo. Your healthcare provider will monitor
you for these complications.
Getting medical treatment right away may help keep these
problems from becoming more serious.
Your healthcare
provider will check you for these problems during your treatment
with Libtayo. Your healthcare provider may treat you with
corticosteroid or hormone replacement medicines. Your healthcare
provider may also need to delay or completely stop treatment with
Libtayo if you have severe side effects.
Before you receive Libtayo, tell your healthcare provider
about all your medical conditions, including if you:
- have immune system problems such as Crohn's disease, ulcerative
colitis, or lupus
- have received an organ transplant
- have received or plan to receive a stem cell transplant that
uses donor stem cells (allogeneic)
- have a condition that affects your nervous system, such as
myasthenia gravis or Guillain-Barré syndrome are pregnant or plan
to become pregnant. Libtayo can harm your unborn baby
Females who are able to become pregnant:
-
- Your healthcare provider will give you a pregnancy test before
you start treatment.
- You should use an effective method of birth control during your
treatment and for at least 4 months after your last dose of
Libtayo. Talk with your healthcare provider about birth control
methods that you can use during this time.
- Tell your healthcare provider right away if you become pregnant
or think you may be pregnant during treatment with Libtayo.
- are breastfeeding or plan to breastfeed. It is not known if
Libtayo passes into your breast milk. Do not breastfeed during
treatment and for at least 4 months after the last dose of
Libtayo.
Tell your healthcare provider about all the medicines you
take, including prescription and over-the-counter medicines,
vitamins, and herbal supplements.
The most common side effects of Libtayo include muscle or bone
pain, tiredness, rash, and diarrhea. These are not all the possible
side effects of Libtayo. Call your doctor for medical advice about
side effects. You may report side effects to FDA at 1-800-FDA-1088.
You may also report side effects to Regeneron Pharmaceuticals and
Sanofi at
1-877-542-8296.
Please see full Prescribing Information,
including Medication Guide.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading
biotechnology company that invents life-transforming medicines for
people with serious diseases. Founded and led for over 30 years by
physician-scientists, our unique ability to repeatedly and
consistently translate science into medicine has led to nine
FDA-approved treatments and numerous product candidates in
development, almost all of which were homegrown in our
laboratories. Our medicines and pipeline are designed to help
patients with eye diseases, allergic and inflammatory diseases,
cancer, cardiovascular and metabolic diseases, pain, hematologic
conditions, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug
development process through our proprietary VelociSuite
technologies, such as VelocImmune, which uses unique
genetically humanized mice to produce optimized fully human
antibodies and bispecific antibodies, and through ambitious
research initiatives such as the Regeneron Genetics Center, which
is conducting one of the largest genetics sequencing efforts in the
world.
For additional information about the company, please visit
www.regeneron.com or follow @Regeneron on Twitter.
About Sanofi
Sanofi is dedicated to supporting people
through their health challenges. We are a global biopharmaceutical
company focused on human health. We prevent illness with vaccines,
provide innovative treatments to fight pain and ease suffering. We
stand by the few who suffer from rare diseases and the millions
with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is
transforming scientific innovation into healthcare solutions around
the globe.
Regeneron Forward-Looking Statements and Use of Digital
Media
This press release includes forward-looking
statements that involve risks and uncertainties relating to future
events and the future performance of Regeneron Pharmaceuticals,
Inc. ("Regeneron" or the "Company"), and actual events or results
may differ materially from these forward-looking statements. Words
such as "anticipate," "expect," "intend," "plan," "believe,"
"seek," "estimate," variations of such words, and similar
expressions are intended to identify such forward-looking
statements, although not all forward-looking statements contain
these identifying words. These statements concern, and these risks
and uncertainties include, among others, the impact of SARS-CoV-2
(the virus that has caused the COVID-19 pandemic) on Regeneron's
business and its employees, collaborators, and suppliers and other
third parties on which Regeneron relies, Regeneron's and its
collaborators' ability to continue to conduct research and clinical
programs, Regeneron's ability to manage its supply chain, net
product sales of products marketed or otherwise commercialized by
Regeneron and/or its collaborators (collectively, "Regeneron's
Products"), and the global economy; the nature, timing, and
possible success and therapeutic applications of Regeneron's
Products and product candidates being developed by Regeneron and/or
its collaborators (collectively, "Regeneron's Product Candidates")
and research and clinical programs now underway or planned,
including without limitation Libtayo® (cemiplimab)
in combination with chemotherapy for the treatment of patients
with locally advanced or metastatic non-small cell lung cancer
("NSCLC"); the likelihood, timing, and scope of possible regulatory
approval and commercial launch of Regeneron's Product Candidates
and new indications for Regeneron's Products, such as possible
regulatory approval of Libtayo in combination with chemotherapy for
the treatment of NSCLC as well as Libtayo (as a monotherapy or in
combination with conventional or novel therapeutic approaches, as
applicable) for the treatment of cervical cancer and other
potential indications; uncertainty of the
utilization, market acceptance, and commercial success of
Regeneron's Products (such as Libtayo) and Regeneron's Product
Candidates and the impact of studies (whether conducted by
Regeneron or others and whether mandated or voluntary), including
the study discussed in this press release, on any of the
foregoing; the ability of Regeneron's collaborators, suppliers, or
other third parties (as applicable) to perform manufacturing,
filling, finishing, packaging, labeling, distribution, and other
steps related to Regeneron's Products and Regeneron's Product
Candidates; the ability of Regeneron to manufacture and manage
supply chains for multiple products and product candidates; safety
issues resulting from the administration of Regeneron's Products
(such as Libtayo) and Regeneron's Product Candidates in patients,
including serious complications or side effects in connection with
the use of Regeneron's Products and Regeneron's Product Candidates
in clinical trials; determinations by regulatory and administrative
governmental authorities which may delay or restrict Regeneron's
ability to continue to develop or commercialize Regeneron's
Products and Regeneron's Product Candidates, including without
limitation Libtayo; ongoing regulatory obligations and oversight
impacting Regeneron's Products, research and clinical programs, and
business, including those relating to patient privacy; the
availability and extent of reimbursement of Regeneron's Products
from third-party payers, including private payer healthcare and
insurance programs, health maintenance organizations, pharmacy
benefit management companies, and government programs such as
Medicare and Medicaid; coverage and reimbursement determinations by
such payers and new policies and procedures adopted by such payers;
competing drugs and product candidates that may be superior to, or
more cost effective than, Regeneron's Products and Regeneron's
Product Candidates; the extent to which the results from the
research and development programs conducted by Regeneron and/or its
collaborators may be replicated in other studies and/or lead to
advancement of product candidates to clinical trials, therapeutic
applications, or regulatory approval; unanticipated expenses; the
costs of developing, producing, and selling products; the ability
of Regeneron to meet any of its financial projections or guidance
and changes to the assumptions underlying those projections or
guidance; the potential for any license, collaboration, or supply
agreement, including Regeneron's agreements with Sanofi, Bayer, and
Teva Pharmaceutical Industries Ltd. (or their respective affiliated
companies, as applicable), to be cancelled or terminated; and risks
associated with intellectual property of other parties and pending
or future litigation relating thereto (including without limitation
the patent litigation and other related proceedings relating to
EYLEA® (aflibercept) Injection, Dupixent®
(dupilumab), Praluent® (alirocumab), and
REGEN-COVTM (casirivimab and imdevimab)), other
litigation and other proceedings and government investigations
relating to the Company and/or its operations, the ultimate outcome
of any such proceedings and investigations, and the impact any of
the foregoing may have on Regeneron's business, prospects,
operating results, and financial condition. A more complete
description of these and other material risks can be found in
Regeneron's filings with the U.S. Securities and Exchange
Commission, including its Form 10-K for the year ended December 31, 2020 and its Form 10-Q for the
quarterly period ended June 30, 2021.
Any forward-looking statements are made based on management's
current beliefs and judgment, and the reader is cautioned not to
rely on any forward-looking statements made by Regeneron. Regeneron
does not undertake any obligation to update (publicly or otherwise)
any forward-looking statement, including without limitation any
financial projection or guidance, whether as a result of new
information, future events, or otherwise.
Regeneron uses its media and investor relations website and
social media outlets to publish important information about the
Company, including information that may be deemed material to
investors. Financial and other information about Regeneron is
routinely posted and is accessible on Regeneron's media and
investor relations website (http://newsroom.regeneron.com) and its
Twitter feed (http://twitter.com/regeneron).
Sanofi Forward-Looking Statements
This press
release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical
facts. These statements include projections and estimates and their
underlying assumptions, statements regarding plans, objectives,
intentions and expectations with respect to future financial
results, events, operations, services, product development and
potential, and statements regarding future performance.
Forward-looking statements are generally identified by the words
"expects", "anticipates", "believes", "intends", "estimates",
"plans" and similar expressions. Although Sanofi's management
believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various
risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual
results and developments to differ materially
from those expressed in, or implied or projected by, the
forward-looking information and statements.
These risks and uncertainties include among other things, the
uncertainties inherent in research and
development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities,
such as the FDA or the EMA, regarding whether and when to approve
any drug, device or biological application that
may be filed for any such product candidates as well as their
decisions regarding labelling and other matters
that could affect the availability or commercial potential of such
product candidates, the fact that product
candidates if approved may not be commercially successful, the
future approval and commercial success of
therapeutic alternatives, Sanofi's ability to benefit from external
growth opportunities, to complete related
transactions and/or obtain regulatory clearances, risks associated
with intellectual property and any related
pending or future litigation and the ultimate outcome of
such litigation, trends in exchange rates and
prevailing interest rates, volatile economic and market
conditions, cost containment initiatives and
subsequent changes thereto, and the impact that COVID-19 will have
on us, our customers, suppliers, vendors, and
other business partners, and the financial condition of any one
of them, as well as on our employees and on the
global economy as a whole. Any material effect of
COVID-19 on any of the foregoing could also
adversely impact us. This situation is changing rapidly and
additional impacts may arise of which we are not
currently aware and may exacerbate other previously identified
risks. The risks and uncertainties also include
the uncertainties discussed or identified in the public filings
with the SEC and the AMF made by Sanofi,
including those listed under "Risk Factors" and "Cautionary
Statement Regarding Forward-Looking Statements"
in Sanofi's annual report on Form 20-F for the year
ended December 31,
2020. Other than as required by applicable law, Sanofi does
not undertake any obligation to update or revise any
forward-looking information or statements.
Regeneron
Contacts:
Media
Relations
Daren Kwok
Tel: +1
914-847-1328
daren.kwok@regeneron.com
|
Investor
Relations
Vesna
Tosic
Tel: +1
914-847-5443
vesna.tosic@regeneron.com
|
Sanofi
Contacts:
Media
Relations
Sally Bain
Tel: +1 781-264-1091
sally.bain@sanofi.com
|
Investor Relations
Paris
Eva
Schaefer-Jansen
Arnaud
Delepine
Nathalie
Pham
Investor Relations
North America
Felix
Lauscher
Fara
Berkowitz
Suzanne
Greco
Tel: +33 (0)1 53 77
45 45
investor.relations@sanofi.com
https://www.sanofi.com/en/investors/contact
|
View original
content:https://www.prnewswire.com/news-releases/esmo-late-breaking-data-show-libtayo-cemiplimab-and-chemotherapy-first-line-treatment-combination-significantly-improved-overall-survival-in-patients-with-advanced-nsclc-301379960.html
SOURCE Regeneron Pharmaceuticals, Inc.